Search Articles
PHILADELPHIA – Hemispherix Biopharma handed out big bonuses to its top dogs despite their misrepresentation of trials of its Ampligen drug, which ended so badly it knocked 43% off the share price in one day, shareholders say in a derivative complaint in state court.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.